FDA
-
-
-
-
-
-
-
ProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer’s disease
-
-
-
-
-
-
-
ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease
-
-
-
322,881 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

